Sun Life (SLF), Medzown Partner to Expand Access to Clinical Trials for Complex Conditions

Sun Life Financial Inc. (NYSE:SLF) is one of the best value stocks to buy right now. On June 16, Sun Life US and Medzown announced a collaboration to increase access to clinical trials for employees of self-insured employers dealing with cancer and complex conditions like orthopedic/musculoskeletal issues. By using Medzown’s AI-powered predictive analytics, Sun Life’s stop-loss clients can identify members at critical diagnostic stages and connect them with advanced therapeutic options and clinical trials.

The partnership aims to address the rising financial burden of high-cost claims, which average over $250,000 for cancer treatments, by providing precision medicine support and personalized patient navigation. A team of scientists and navigators will work directly with members and their care teams, acting as an extension of existing benefits to ensure a supported path to effective, cutting-edge therapies.

Sun Life (SLF), Medzown Partner to Expand Access to Clinical Trials for Complex Conditions

This initiative expands Sun Life Financial Inc.’s (NYSE:SLF) suite of health solutions, which already includes clinical reviews and expert cancer second opinions. By proactively managing complex diagnoses, the collaboration seeks to improve patient health outcomes while simultaneously reducing long-term specialty drug cost exposure for self-funded employers.

Sun Life Financial Inc. (NYSE:SLF) is a financial services company that provides asset management, wealth, insurance, and health solutions to individual and institutional customers internationally.

While we acknowledge the risk and potential of SLF as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SLF and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1